tradingkey.logo

ARS Pharmaceuticals Inc <SPRY.OQ> expected to post a loss of 35 cents a share - Earnings Preview

ReutersMay 12, 2025 1:07 PM
  • ARS Pharmaceuticals Inc SPRY.OQ SPRY.O is expected to show a rise in quarterly revenue when it reports results on May 14 for the period ending March 31 2025

  • The San Diego California-based company is expected to report revenue of $7.482 million, according to the mean estimate from 6 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for ARS Pharmaceuticals Inc is for a loss of 35 cents per share.

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had fallen by about 1.8% in the last three months. ​

  • Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $30.00​, above​ its last closing price of $13.44. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.10

-0.14

0.49

Beat

450

Sep. 30 2024

-0.15

-0.15

-0.20

Missed

-35.6

Jun. 30 2024

-0.13

-0.12

-0.13

Missed

-11.4​

Mar. 31 2024

-0.12

-0.11

-0.11

Met

0

​​Dec. 31 2023

-0.11

-0.14

-0.07

Beat

50

Sep. 30 2023

-0.19

-0.18

-0.16

Beat

12.4​

Jun. 30 2023

-0.19

-0.17

-0.18

Missed

-3.6

Mar. 31 2023

-0.17

-0.17

-0.16

Beat

4.6

This summary was machine generated May 12 at 13:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI